Cost Curve News - News - https://www.costcurvenews.com/blog/page/7/

Tariffs and MFN Dominate the Headlines, But Details Remain Scant

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

PBMs Are Trying to Sell CMS on a ‘Splashy Announcement’ That PBMs Will (Voluntarily) Do the Right Thing

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

A New Antibiotic Might Make for the Most Interesting Pricing Story of the Year

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

Injected Versions of Cancer Meds Make Life Easier for Patients and Drive Savings for Clinicians. There Is a Backlash Anyway

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

It’s Formulary Season, and Early Analyses Suggest Big Changes in How PBMs Approach Biosims

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

The FDA Assault on DTC Advertising Is Targeting a Lot More Than Just TV Ads

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

Payers Say COVID and Flu Vaccine Reimbursements Will Remain Solid, Regardless of CDC Changes

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

The Second-Day Reaction to the DTC Letters: Oprah Gets a Look, Pharma Gets Targeted, and FDA’s Capacity Gets Questioned

It’s a quick one today. I’m on the road, attending the Oliver Wyman Health Innovation Summit. I had the opportunity to share the stage yesterday with ICER’s Sarah Emond, and

A Smart Tufts CEVR Look at Every Cost-Effectiveness Analysis Published for the Meds CMS Is Currently ‘Negotiating’

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv